Wednesday, February 10, 2010, 11:00pm SGT - The Singapore stock market is closed.
To create a watchlist or portfolio of shares, Register
FINANCE HOME PAGEINVESTINGFINANCE NEWS
    Market:       |  

Impax Laboratories Inc. (IPXL)

At 10:44PM SGT: 13.60 USD  Down 0.06 (0.44%)  
 MORE ON IPXL 
Quotes
HereSummary
Charts
News & Info
Company
Analyst Coverage
Ownership
Financials
 Impax Laboratories, Inc. (NGM:IPXL) Delayed quote dataEdit
Last Trade:13.60 USD
Trade Time:10:44PM SGT
Change:Down 0.06 (0.44%)
Prev Close:13.66
Open:13.67
Bid:13.59 x 600
Ask:13.66 x 200
1y Target Est:16.00
Day's Range:13.60 - 13.65
52wk Range:3.00 - 14.87
Volume:4,335
Avg Vol (3m):586,606
Market Cap:841.49M
P/E (ttm):34.96
EPS (ttm):0.39
Div & Yield:N/A (N/A%)
[Chart]
1d  5d  3m  6m  1y  2y 
Use Y! Toolbar to track stocks
 Add IPXL to Portfolio   Download Data

 HEADLINES 
•2010 Health Care Stock Winners With Or Without Congressional Legislation
Wall Street Transcript (Thu, Jan 28)
•Molecular Diagnostics And Point Of Care Diagnostics Companies Lead Buy List From Bleichroeder For 2010
Wall Street Transcript (Mon, Jan 25)
•Impax Laboratories Earnings Call scheduled for Thu, Feb 25
CCBN (Fri, Jan 22)
•Impax Laboratories Schedules Conference Call for Fourth Quarter and Full Year 2009 Financial Results
Business Wire (Thu, Jan 21)
•Impax challenges Genzyme, partner on Welchol
AP (Sat, Jan 16)
•UPDATE - Daiichi Sankyo's cholesterol drug gets generic threat
at Reuters (Fri, Jan 15)
•Impax Laboratories Confirms Patent Challenge Relating to WELCHOL® 625 mg Tablets
Business Wire (Fri, Jan 15)
•IMPAX LABORATORIES INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibi
EDGAR Online (Fri, Jan 15)
•IMPAX LABORATORIES INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
EDGAR Online (Tue, Jan 12)
•Top Sectors for 2010: 1 Minute Trade
TheStreet.com TV (Mon, Jan 11)
More Headlines for IPXL...
 ANALYST 
EPS Est (next year) (Dec-09) :0.34
EPS Est (in 2 years) (Dec-10) :0.92
Avg Rec (current)*:2.1
PEG Ratio:1.15
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

 BUSINESS SUMMARY 
Impax Laboratories, Inc. engages in the development and commercialization of bioequivalent and brand-name pharmaceuticals. It operates through two divisions, Global Pharmaceuticals and Impax Pharmaceutical.

Full Company Profile



Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Search by Company
•Latest News•Singapore Indices